Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.63 |
| ▸ | NOS3 | P29474 | 6/20 | 0.63 |
| ▸ | NOS1 | P29475 | 5/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790110 | 0.83 | NOS3 (0.50) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL31462838 | 0.80 | NOS2 (0.41) | NOS2NOS3NOS1ALDH1A1KMT2A | |
| SCHEMBL12015758 | 0.79 | NOS2 (0.59) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL7050708 | 0.77 | NOS2 (1.00) | NOS2NOS3NOS1 | |
| SCHEMBL2717960 | 0.77 | NOS2 (0.57) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL171325 | 0.77 | — | — | |
| SCHEMBL799308 | 0.76 | NOS3 (0.45) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL1706050 | 0.76 | NOS2 (0.55) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL28303965 | 0.76 | NOS2 (0.55) | NOS2NOS3NOS1HRH3MEN1 | |
| SCHEMBL29338762 | 0.76 | NOS2 (0.55) | NOS2NOS3NOS1HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | NOS2 3730/4885NOS3 2905/4885NOS1 3357/4885 |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | NOS2 645/4885NOS3 724/4885NOS1 865/4885 |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | NOS2 3719/4885NOS3 3323/4885NOS1 3515/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | NOS2 2286/4885NOS3 2046/4885NOS1 3286/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | NOS2 329/4885NOS3 334/4885NOS1 208/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | NOS2 2303/4885NOS3 3275/4885NOS1 2434/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | NOS2 645/4885NOS3 724/4885NOS1 865/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | NOS2 1075/4885NOS3 1318/4885NOS1 1279/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | NOS2 2286/4885NOS3 2046/4885NOS1 3286/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | NOS2 3730/4885NOS3 2905/4885NOS1 3357/4885 |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | PDPK1, PDK1, PDK3 | NOS2 2042/4885NOS3 1848/4885NOS1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.